Walleye Capital
SAGE

Walleye Capital’s Sage Therapeutics SAGE Stock Holding History

Walleye Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,290
Closed -$322K – 5053
2025
Q2 		$322K Buy
35,290
+23,343
+195% +$172K ﹤0.01% 2992
2025
Q1 		$95K Sell
11,947
-44,126
-79% -$323K ﹤0.01% 3650
2024
Q4 		$304K Sell
56,073
-164,900
-75% -$1.01M ﹤0.01% 3412
2024
Q3 		$1.6M Buy
220,973
+92,229
+72% +$844K ﹤0.01% 2190
2024
Q2 		$1.4M Buy
128,744
+62,428
+94% +$800K ﹤0.01% 2484
2024
Q1 		$1.24M Sell
66,316
-3,443
-5% -$79.4K ﹤0.01% 2378
2023
Q4 		$1.51M Buy
+69,759
New +$1.38M ﹤0.01% 2005
2023
Q3 		– Sell
-54,561
Closed -$1.58M – 5271
2023
Q2 		$2.57M Buy
+54,561
New +$2.71M 0.01% 1167
2022
Q3 		– Sell
-33,199
Closed -$1.28M – 3495
2022
Q2 		$1.07M Buy
+33,199
New +$1.11M 0.03% 615
2022
Q1 		– Sell
-75,679
Closed -$3.22M – 2557
2021
Q4 		$3.22M Buy
+75,679
New +$3.17M 0.1% 225
2020
Q2 		– Sell
-18,445
Closed -$530K – 921
2020
Q1 		$530K Buy
+18,445
New +$1.07M 0.12% 217
2019
Q4 		– Sell
-9,199
Closed -$1.29M – 2204
2019
Q3 		$1.29M Buy
+9,199
New +$1.54M 0.08% 351

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Walleye Capital's SAGE Position: Q3 2025 in Review

Walleye Capital sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 35,290 shares — an estimated $322K sold.

Walleye Capital first reported a position in SAGE in Q3 2019 and held it in 12 quarters. The position peaked at $3.22M in Q4 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Walleye Capital reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 35,290 Sage Therapeutics shares in Q3 2025, an estimated $322K.
  • Walleye Capital first reported a position in Sage Therapeutics in Q3 2019 and held it in 12 quarters.
  • Walleye Capital's Sage Therapeutics position peaked at $3.22M in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.